Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 243-247

  Rodriguez, Carlos A ^a   Agudelo, Maria ^a   Zuluaga, Andres F ^a   Vesga, Omar ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; GENTAMICIN; OXACILLIN; PENICILLIN G; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOLYSIS; BACTEREMIA; BACTERIUM COLONY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG CONCENTRATION; FEMALE; INFECTION RESISTANCE; LIVER GRAFT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THIGH; THIGH INFECTION; TISSUE HOMOGENATE;

ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUGS, GENERIC; FEMALE; HUMANS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; STAPHYLOCOCCAL INFECTIONS; THERAPEUTIC EQUIVALENCY; THIGH; TISSUE EXTRACTS; VANCOMYCIN;

EID: 84455169949     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05129-11     Document Type: Article

References (24)

1. Boyle-Vavra S, Berke SK, Lee JC, Daum RS. 2000. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44:272-277. (Pubitemid 30060718)
2. Boyle-Vavra S, Challapalli M, Daum RS. 2003. Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin- intermediate resistance. Antimicrob. Agents Chemother. 47:2036-2039. (Pubitemid 36637841)
3. Clinical Laboratory Standards Institute. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. Clinical Laboratory Standards Institute, Wayne, PA.
4. Cui L, et al. 2006. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:428-438. (Pubitemid 43190949)
5. Cui L, et al. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14. (Pubitemid 36098547)
6. Firsov AA, Vostrov SN, Shevchenko AA, Cornaglia G. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287. (Pubitemid 27231427)
7. Gustafson JE, Berger-Bachi B, Strassle A, Wilkinson BJ. 1992. Autolysis of methicillin-resistant and -susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 36:566-572.
8. Hiramatsu K, et al. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673. (Pubitemid 28036828)
9. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
10. Khatib R, et al. 2006. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand. J. Infect. Dis. 38:7-14. (Pubitemid 43123837)
11. Mwangi MM, et al. 2007. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. U. S. A. 104:9451-9456. (Pubitemid 47185800)
12. Neuner EA, Casabar E, Reichley R, McKinnon PS. 2010. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagn. Microbiol. Infect. Dis. 67:228-233.
13. Rodriguez CA, Agudelo M, Catano JC, Zuluaga AF, Vesga O. 2009. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J. Infect. 59:277-280.
14. Rodriguez CA, Agudelo M, Graciano NA, Zuluaga AF, Vesga O. 2006. Generic vancomycin enriches resistant subpopulations of S. aureus after treatment in the neutropenic mouse thigh infection model. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. abstr A-648.
15. Rodriguez CA, Agudelo M, Zuluaga AF, Vesga O. 2010. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin. BMC Infect. Dis. 10:153.
16. Rybak MJ, et al. 2009. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29:1275-1279.
17. Sakoulas G, et al. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402. (Pubitemid 38747480)
18. Sieradzki K, Tomasz A. 2006. Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate Staphylococcus aureus-type resistance, cell concentration dependence of the MIC, and antibiotic tolerance in vancomycin-susceptible S. aureus. Antimicrob. Agents Chemother. 50:527-533. (Pubitemid 43190962)
19. Stratton CW. 2003. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg. Infect. Dis. 9:10 -16.
20. Utaida S, et al. 2003. Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology 149:2719-2732. (Pubitemid 37279247)
21. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. 2010. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob. Agents Chemother. 54:3271-3279.
22. Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ. 2010. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J. Antimicrob. Chemother. 65:1015-1018.
23. Zuluaga AF, Agudelo M, Cardeno JJ, Rodriguez CA, Vesga O. 2010. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model. PLoS One 5:e10744.
24. Zuluaga AF, et al. 2006. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect. Dis. 6:55.